January 3, 2014
This article was reported by Healio.
An article in Healio concluded that patients with hepatitis C virus (HCV) infection and TB coinfection have a greater risk of drug-induced hepatotoxicity to the first-line anti-TB drugs isoniazid, rifampin, and pyrazinamide.
Researchers from the National Center for TB and Lung Diseases in Tbilisi, Georgia, studied 326 TB patients from March 2007 to March 2010. Of these participants, 68 (21 percent) were coinfected with HCV. The researchers excluded 38 participants who were not available for follow-up, leaving 288 participants in the study. Of these 288 participants, 54 developed hepatotoxicity: 42 had grade 1, eight had grade 2, and four had grade 3 hepatotoxicity. Multivariable analysis showed that HCV coinfection was associated significantly with hepatotoxicity among TB patients. Also, participants with HCV coinfection developed hepatotoxicity in a shorter time than those without HCV.
The researchers concluded that there was a low risk of severe hepatotoxicity even in patients with TB and HCV coinfection. They noted that patients with active TB disease and HCV coinfection who had normal baseline liver function did not need routine monitoring of monthly serum alanine aminotransferase activity during treatment with first-line anti-TB drugs.
The full report, "Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity Among Patients with Pulmonary Tuberculosis," was published in the journal PLoS One (2013;doi:10.1371/journal.pone.0083892).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|The Curious Case of M184V, Part 1|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|
|Fat Gains Continue and Lean Mass Falls in Group on Long-Term HIV Therapy|
|The Best HIV Cure Will Be Built With Us, Not Just for Us|